Liposomal daunorubicin (Daunoxome) in the treatment of acute lymphocytic leukemia (ALL).

被引：0
|
作者：
Baccarani, M [1 ]
Russo, D [1 ]
Fanin, R [1 ]
Michieli, M [1 ]
机构：
[1] Univ Hosp, Div Hematol, Udine, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3110
引用
收藏
页码：720A / 720A
页数：1
相关论文
共 50 条
  • [31] BCG IN TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
    HEYN, R
    BORGES, W
    JOO, P
    KARON, M
    NESBIT, M
    SHORE, N
    BRESLOW, N
    HAMMOND, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1973, 14 (MAR): : 45 - &
  • [32] Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
    Ronson, Aaron
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 369 - 374
  • [33] Liposomal daunorubicin (Daunoxome) results in higher plasma concentrations but similar intracellular concentrations in leukemic cells compared to non-encapsulated daunorubicin during induction treatment in acute myeloid leukemia (AML).
    Lehmann, S
    Bengtzen, S
    Tidefelt, U
    Lofgren, C
    Mollgard, L
    Paul, C
    BLOOD, 2003, 102 (11) : 255B - 255B
  • [34] Treatment of primary aggressive lymphoma with liposomal daunorubicin (Daunoxome(R)) substitution in CHOP regimen.
    Nikitin, EA
    Iahnina, EI
    Pivnik, AV
    Medvedev, PV
    Marjin, DS
    Astsaturov, IA
    BLOOD, 1997, 90 (10) : 3978 - 3978
  • [35] Daunorubicin and daunorubicinol levels in human glioma tumors after administration of liposomal encapsulated daunorubicin (Daunoxome)
    Zucchetti, M
    Boiardi, A
    Silvani, A
    Parisi, I
    Piccolrovazzi, S
    D'Incalci, M
    ANNALS OF ONCOLOGY, 1998, 9 : 128 - 128
  • [36] Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients
    Andrea Camera
    Ciro R. Rinaldi
    Salvatore Palmieri
    Nicola Cantore
    Giuseppina Mele
    Vincenzo Mettivier
    Eustachio Miraglia
    Lucia Mastrullo
    Francesco Grimaldi
    Luigia Luciano
    Anna Guerriero
    Bruno Rotoli
    Felicetto Ferrara
    Annals of Hematology, 2009, 88 : 151 - 158
  • [37] A phase I trial of liposomal daunorubicin (Daunoxome®) administered with high-dose cytarabine (HiDAC) to patients (pts) with relapsed acute leukemia (AL).
    Cripe, L
    Kneebone, P
    Roberts, L
    Mukwaya, G
    Rutledge, C
    Gordon, M
    BLOOD, 1998, 92 (10) : 233A - 233A
  • [38] DAUNORUBICIN CARDIAC TOXICITY IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA
    HALAZUN, JF
    WAGNER, HR
    GAETA, JF
    SINKS, LF
    CANCER, 1974, 33 (02) : 545 - 554
  • [39] Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome
    Bellott, R
    Pouna, P
    Robert, J
    JOURNAL OF CHROMATOGRAPHY B, 2001, 757 (02): : 257 - 267
  • [40] Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia
    Pea, F
    Russo, D
    Michieli, M
    Baraldo, M
    Ermacora, A
    Damiani, D
    Baccarani, M
    Furlanut, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (04) : 279 - 286
12345